CSPC：SYS6043 is proposed to be granted Breakthrough Therapy designation.
Astellas：PADCEV®Enfortumab vedotinreceived marketing approval
Sino：LM-302 has been formally accepted for review.
Pfizer：Sigvotatug vedotin failed in Phase III.
Haisco: Recently entered into an exclusive license agreement with Nuvectis Pharma, Inc. in the United States.
Takeda：ADZYNMA®Apadamtase alfa marketing application submitted
AstraZeneca：TAGRISSO®Osimertinib approved for marketing in China.
Biokin：BL-B01D1 approved for marketing in China.
CARsgen：satri-cel approved for marketing in China.
Genrix：GR1801 was approved
